Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma

Area of Science:

• Gynecologic Oncology
• Immunology
• Cancer Research

Background:

• Endometrial carcinoma presents a growing global health challenge due to increasing incidence and mortality.
• Upregulation of programmed death ligand 1 (PD-L1) on tumor cells inhibits anti-tumor immunity and promotes tumor survival.
• Understanding PD-L1 expression is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate programmed death ligand 1 (PD-L1) expression in endometrial carcinoma.
• To correlate PD-L1 expression levels with patient survival rates.

Main Methods:

• Immunohistochemistry was utilized to assess PD-L1 expression.
• PD-L1 expression was quantified on both tumor cells and tumor-infiltrating immune cells.
• A cohort of 59 endometrial carcinoma cases and 32 non-neoplastic endometrial tissue controls were analyzed.

Main Results:

• PD-L1 expression was detected in 62.7% of immune cells and 28.8% of tumor cells.
• Immune cell PD-L1 expression was significantly higher in endometrial carcinoma compared to controls (p < 0.001).
• Tumor cell PD-L1 expression was significantly associated with poorer survival (p < 0.001), observed in 66.7% of deceased patients versus 15.9% of survivors.

Conclusions:

• PD-L1 expression in tumor cells is a significant indicator of poor prognosis in endometrial carcinoma.
• Targeted immunomodulation using PD-L1 inhibitors may offer a therapeutic strategy for advanced endometrial cancer.